These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29961127)

  • 1. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.
    Alconcher LF; Coccia PA; Suarez ADC; Monteverde ML; Perez Y Gutiérrez MG; Carlopio PM; Missoni ML; Balestracci A; Principi I; Ramírez FB; Estrella P; Micelli S; Leroy DC; Quijada NE; Seminara C; Giordano MI; Hidalgo Solís SB; Saurit M; Caminitti A; Arias A; Rivas M; Risso P; Liern M
    Pediatr Nephrol; 2018 Oct; 33(10):1791-1798. PubMed ID: 29961127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 levels and neurologic involvement in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli.
    Balestracci A; Meni Battaglia L
    Pediatr Nephrol; 2020 Oct; 35(10):2009-2010. PubMed ID: 32728842
    [No Abstract]   [Full Text] [Related]  

  • 3. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic uremic syndrome related to Shiga-like toxin-producing Escherichia coli with encephalitis hiding a human herpesvirus-6 infection: a case report.
    Mounier S; Gavotto A; Tenenbaum J; Meyer P; Fila M; Baleine J
    J Med Case Rep; 2021 May; 15(1):300. PubMed ID: 34034812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.
    Balestracci A; Meni Bataglia L; Toledo I; Beaudoin L; Alvarado C
    Pediatr Nephrol; 2020 Feb; 35(2):331-339. PubMed ID: 31475299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.
    Mody RK; Luna-Gierke RE; Jones TF; Comstock N; Hurd S; Scheftel J; Lathrop S; Smith G; Palmer A; Strockbine N; Talkington D; Mahon BE; Hoekstra RM; Griffin PM
    Arch Pediatr Adolesc Med; 2012 Oct; 166(10):902-9. PubMed ID: 22869280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes.
    Joseph A; Rafat C; Zafrani L; Mariani-Kurkdjian P; Veyradier A; Hertig A; Rondeau E; Mariotte E; Azoulay E
    Crit Care Med; 2018 Sep; 46(9):e904-e911. PubMed ID: 29979220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany.
    Frank C; Werber D; Cramer JP; Askar M; Faber M; an der Heiden M; Bernard H; Fruth A; Prager R; Spode A; Wadl M; Zoufaly A; Jordan S; Kemper MJ; Follin P; Müller L; King LA; Rosner B; Buchholz U; Stark K; Krause G;
    N Engl J Med; 2011 Nov; 365(19):1771-80. PubMed ID: 21696328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.
    Ko H; Maymani H; Rojas-Hernandez C
    J Med Case Rep; 2016 Jun; 10():175. PubMed ID: 27301547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.
    Nathanson S; Kwon T; Elmaleh M; Charbit M; Launay EA; Harambat J; Brun M; Ranchin B; Bandin F; Cloarec S; Bourdat-Michel G; Piètrement C; Champion G; Ulinski T; Deschênes G
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1218-28. PubMed ID: 20498239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network.
    Ardissino G; Tel F; Testa S; Paglialonga F; Longhi S; Martelli L; Consolo S; Picicco D; Dodaro A; Daprai L; Colombo R; Arghittu M; Perrone M; Chidini G; Scalia Catenacci S; Cropanese I; Consonni D;
    Eur J Pediatr; 2018 Nov; 177(11):1667-1674. PubMed ID: 30094644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHARACTERISTICS OF DIARRHEAL DISEASE COMPLICATED WITH HEMOLYTIC UREMIC SYNDROME AMONG CHILDREN IN GEORGIA, 2009-2016.
    Chokoshvili O; Vepkhvadze N; Davitaia T; Tevzadze L; Tsertsvadze T
    Georgian Med News; 2018 Oct; (283):123-129. PubMed ID: 30516507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
    Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
    Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Adverse Outcomes for Shiga Toxin-Producing Escherichia coli Infections in Emergency Departments.
    Lin CY; Xie J; Freedman SB; McKee RS; Schnadower D; Tarr PI; Finkelstein Y; Desai NM; Lane RD; Bergmann KR; Kaplan RL; Hariharan S; Cruz AT; Cohen DM; Dixon A; Ramgopal S; Powell EC; Kilgar J; Michelson KA; Bitzan M; Yen K; Meckler GD; Plint AC; Balamuth F; Bradin S; Gouin S; Kam AJ; Meltzer JA; Hunley TE; Avva U; Porter R; Fein DM; Louie JP; Tarr GAM;
    J Pediatr; 2021 May; 232():200-206.e4. PubMed ID: 33417918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.
    Karnisova L; Hradsky O; Blahova K; Fencl F; Dolezel Z; Zaoral T; Zieg J
    Eur J Pediatr; 2018 Dec; 177(12):1837-1844. PubMed ID: 30251107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement Gene Variants and Shiga Toxin-Producing
    Frémeaux-Bacchi V; Sellier-Leclerc AL; Vieira-Martins P; Limou S; Kwon T; Lahoche A; Novo R; Llanas B; Nobili F; Roussey G; Cailliez M; Ulinski T; Deschênes G; Alberti C; Weill FX; Mariani P; Loirat C
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):364-377. PubMed ID: 30674459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].
    Loirat C
    Rev Prat; 2013 Jan; 63(1):11-6. PubMed ID: 23457821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.